Locally Advanced Rectal Cancer – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026

Locally Advanced Rectal Cancer Emerging Therapy and TPP Insights

Thelansis’s “Locally Advanced Rectal Cancer Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Locally Advanced Rectal Cancer Overview

Locally advanced rectal cancer (LARC) generally refers to stage II–III tumors that extend beyond the rectal wall or involve regional nodes without distant metastasis. Symptoms include rectal bleeding, altered bowel habits, urgency, pelvic discomfort, or anemia, although some cases are detected through screening. Pelvic MRI and testing for mismatch-repair deficiency or microsatellite instability help guide treatment. For most microsatellite-stable tumors, care may include total neoadjuvant therapy—chemotherapy with radiation—followed by surgery; selected patients with a complete clinical response may choose close surveillance instead of immediate surgery. For stage II/III MSI-H or dMMR disease, the FDA approved dostarlimab in October 2026, offering eligible adults an immunotherapy-first option that may allow chemotherapy, radiation, and surgery to be avoided if a complete response is achieved. Suitability varies, so multidisciplinary assessment and ongoing surveillance remain essential.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs

*Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
  • Pipeline analysis
  • Target patients for emerging therapies
  • Key companies
  • Key mechanism of actions
  • Launch date estimates, etc.
• Clinical trial landscape analysis
  • Target patient segments
  • Trial endpoints
  • Trial design
  • Recruitment criteria, etc.
• Unmet Needs and Opportunities
  • Performance of key current therapies
  • Top areas of unmet needs
  • Opportunity sizing for key unmet needs
• Target Product Profiles
  • Attributes and levels
  • Physician likelihood of prescribing
  • Expected patient shares
• KOL insights on key emerging therapies
  • Level of awareness
  • Expected use / line of therapy
  • Extent to fulfil key unmet needs
  • KOL quotes

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.

2. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies – profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key emerging therapies – profiles and KOL insights

3. Product Attribute Analysis

• Key takeaways
• Scientific attributes
• Commercial attributes
• Product positioning

4. Primary Market Research

• Current treatment landscape
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Current challenges
  • Unmet needs
• Emerging therapies
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Unmet needs and KOL expectations

5. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

6. Regulatory and Reimbursement Environments (by country and payer insights)

7. Appendix (e.g., bibliography, methodology)